Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on April 17th, 2025 | 08:10 CEST
Blockbuster or takeover fever? Why Novo Nordisk, Defence Therapeutics, and Pfizer are now attracting attention
The biotech and pharmaceutical industry resembles a billion-dollar chessboard! A single move – whether a takeover or drug approval – can double share prices in a matter of hours or completely reshape entire markets. While investors are still marveling at the spectacular rally of Theratechnologies, which opened with a gap up and then soared another 45% in a single day, or analyzing the Phase-3 explosion at Corcept, the next players are already lining up for the big coup. Because in this arena, it is not just about who develops the next blockbuster but also who buys, sells, or forms strategic alliances. There are three names to have on your radar: Novo Nordisk, Defence Therapeutics, and Pfizer. Each of these companies is pursuing its own master plan.
Read
Commented by Armin Schulz on April 14th, 2025 | 07:20 CEST
123fahrschule is booming, while Volkswagen and Mercedes-Benz are struggling with tariffs and e-mobility
The German automotive industry is struggling with punitive tariffs and declining competitiveness, while the driving school sector is booming – a paradox of future markets. As Volkswagen and Mercedes-Benz face export declines and try to integrate the electric revolution into their existing structures, 123fahrschule is focusing on digital learning concepts and sustainability. But what connects luxury automakers with driving schools? Both face the question of how to master technology, global crises, and younger target groups. Innovation requires more than horsepower and premium labels. We look at how 123fahrschule, Volkswagen, and Mercedes-Benz meet these challenges and aim to shape the future.
Read
Commented by Armin Schulz on April 14th, 2025 | 06:50 CEST
Gold shines as a safe haven – Tocvan Ventures sets new standards with its Mexico project
With a gold price above USD 3,100 per ounce, the precious metal remains a stable anchor in uncertain times. For investors seeking to profit disproportionately from this dynamic, exploration companies with promising projects are coming into focus. One of the most exciting players is Tocvan Ventures, which recently presented spectacular drilling results from its Gran Pilar project in Sonora, Mexico. The Company is strategically well-positioned to benefit from the increasing demand for gold and silver – and is now offering investors an attractive entry scenario.
Read
Commented by Armin Schulz on April 9th, 2025 | 07:00 CEST
From diabetes to cancer: How Novo Nordisk, NetraMark, and BioNTech are reinventing medicine
The medicine of tomorrow is being written today – with algorithms that personalize therapies, mRNA vaccines that fight cancer, and drugs that conquer chronic diseases. While AI is revolutionizing clinical trials and shifting billion-dollar markets, biotech pioneers are fighting for dominance in precision medicine. Who is driving this transformation? Three companies are in the spotlight: Novo Nordisk, a pioneer in the fight against diabetes and obesity; NetraMark, whose AI is decoding clinical trials; and BioNTech, which is redefining oncology with mRNA. Their innovations are not just dreams of the future – they are already changing how lives are saved and extended.
Read
Commented by Armin Schulz on April 8th, 2025 | 07:30 CEST
Bayer, BioNxt Solutions, Evotec – False tariff alarm for pharma and biotech! Which stocks are worth buying?
The provisional exemption from tariffs for medicines and pharmaceutical products offers the industry a breather – but appearances are deceptive. Based on WTO rules, the exemptions protect German exports in the multi-billion-dollar US market. However, indirect risks lurk in the form of rising costs for raw materials, political unpredictability, and dependence on global supply chains. While the sector can breathe a sigh of relief in the short term, long-term trade conflicts are forcing strategic maneuvering. For Bayer, the US market is very important. BioNxt Solutions is developing disruptive drug delivery solutions, and Evotec aims to redefine drug discovery with artificial intelligence. Let's take a closer look at these three companies.
Read
Commented by Armin Schulz on April 8th, 2025 | 07:10 CEST
Palantir US-Tech stocks plummet – MiMedia defies the storm, Xiaomi makes strategic decisions
The global financial markets are undergoing an unprecedented stress test. The latest tariff measures by the Trump administration have ignited a trade conflict that is putting technology companies at the center of the turbulence. While US companies such as Apple and Nvidia are suffering from supply chain disruptions and plunging share prices, the technology sector is on the brink of a turning point. However, not all players are reacting in the same way. Palantir shares have recently plummeted, while MiMedia, a cloud specialist, is successfully focusing on disruptive business models – and Xiaomi is demonstrating resilience. In this environment, we take a closer look at the individual stocks.
Read
Commented by Armin Schulz on April 4th, 2025 | 07:10 CEST
Bayer's cancer drugs, Defence Therapeutics' cancer vaccine, Novo Nordisk's fat burner – Back on the road to success through specialization
The new trade tariffs threaten to destabilize the global supply chains of the pharmaceutical industry, increase the prices of generic drugs, and slow innovation cycles. The only winners in this environment will be those who focus on unique innovations to ensure resilience and growth. Bayer is trying to make itself fit for the future with an efficiency program, new pharmaceutical products, and digital agriculture platforms. Defence Therapeutics excels with precision-medicine cancer vaccines based on patented technology, opening up new markets. Novo Nordisk, in turn, is shaping a multibillion-dollar market with GLP-1 therapies for obesity and diabetes based on closed production cycles. These three approaches show how specialization and adaptability open new paths in turbulent times.
Read
Commented by Armin Schulz on April 3rd, 2025 | 07:30 CEST
Tungsten shortage as a goldmine: Why Almonty Industries is becoming a key player for NATO countries
As early as the beginning of December 2024, there were initial indications that China would impose certain restrictions on its tungsten exports. After the Chinese government further tightened export control on tungsten and molybdenum in early February 2025, Western industries have been increasingly seeking reliable alternatives. While Beijing leverages its dominance in critical metals as a geopolitical lever, companies like Almonty Industries are benefiting by building independent supply chains. With strategic partnerships, a relocation of its headquarters to the US, and the revival of one of South Korea's largest tungsten mines, the Company is positioning itself as a key player in a market characterized by scarcity and increasing demand.
Read
Commented by Armin Schulz on April 2nd, 2025 | 07:20 CEST
dynaCERT: Government-backed, certified, profitable – Driving your returns green
The Ontario government is leading by example – and dynaCERT could be one of the beneficiaries. The Canadian cleantech company, known for its revolutionary HydraGEN™ technology, is receiving government support in a market that is hungry for solutions for more efficient mobility and measurable CO₂ reductions. In an era when climate goals and economic considerations can no longer be at odds, dynaCERT is positioning itself as a bridge between ecology and economy. A new player is emerging here in the billion-dollar market for emission certificates.
Read
Commented by Armin Schulz on April 2nd, 2025 | 07:10 CEST
Steyr Motors, Power Metallic Mines, BYD – From unique selling point to market leader
In the context of geopolitical tariffs and green transformation, drive technology, raw material extraction, and e-mobility are merging into key sectors. While US automotive tariffs are setting new rules from 2025, three players are driving systemic solutions: Steyr Motors, a pioneer in high-performance hybrid engines; Power Metallic Mines, which is setting ESG standards with carbon-neutral nickel; and BYD, which is dominating e-mobility through innovation. Their strategies – technological sovereignty, vertical integration, and resource-efficient ecosystems – demonstrate how the apparent contradictions between decarbonization and industrial reality can be overcome. Three companies, one mission: to shape the value chain of tomorrow.
Read